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With an incidence of 1:7000 births, cystinuria, the most frequent cause of stone
formation among genetic diseases, represents a major medical problem. Twenty-
ﬁve cystine stones randomly selected from cystinuric patients were investigated.
From a crystallographic point of view, cystine stones are composed of
micrometre size crystallites, which are made up of an aggregation of
nanocrystals. Through scanning electron microscopy, the morphology and size
of the crystallites have been described, while the size of the nanocrystals was
investigated by means of powder neutron diffraction. Powder neutron
diffraction analysis and/or scanning electron microscopy examination of cystine
stones provide evidence that usual alkalinization by sodium bicarbonate
associated with high diuresis signiﬁcantly reduces the size of both nanocrystals
and crystallites, while for other treatments, including alkalinizing drugs and thiol
derivatives, the data suggest mainly changes in the topology of crystallites.
Alkalinization with sodium bicarbonate affects cystine kidney stones at the
mesoscopic and nanoscopic scales, while other medical treatments only alter
their surface. Such an approach may help to assess the interaction between drugs
and cystine stones in cystinuric patients.
1. Introduction
Cystinuria comes from a mutation in renal epithelial cell
transporters which induces a signiﬁcant reduction in dibasic
amino acids and cystine reabsorption and a high excretion of
these amino acids, mainly lysine and cysteine (Dent & Rose,
1974; Letavernier et al., 2012). Cystinuria represents a major
medical problem because of stone recurrence and the risk to
induce renal failure. Worldwide, its incidence is about 1:7000
births (Stephens, 1989; Barbey et al., 2000). It is the most
frequent cause of stone formation among genetic diseases.
Cystine stones represent about 1% of kidney stones in adults
and they are more frequent in stone-forming children
(accounting for up to 8%) (Stapleton et al., 1987; Tekin et al.,
2001). The disease expression as well as the incidence of
cystine calculi vary with the genetic subtype (Goodyer et al.,
1998; Gasparini et al., 1995). Owing to its poor solubility,
cystine easily crystallizes in the nephrons and the urinary tract
(Goldfarb et al., 2006; Brauers et al., 2006). Prevention of stone
recurrence is based on high diuresis (>3 l d1), alkalinization
by bicarbonate and/or citrate salts and, if needed, thiol deri-
vatives which are able to form complexes with cysteine more
soluble in urine than cysteine (Dolin et al., 2005). Observa-
tions of kidney stones through stereomicroscopy show that
these therapies may modify at the macroscopic scale the
morphology of calculi.
Thus, two morphological types of cystine kidney stones
(KS), namely Va and Vb, may be distinguished (Bhatta et al.,
1989; Daudon et al., 1993; Kim et al., 2005), on the basis of
their surface characteristics as observed through a stereo-
microscope. As previously described, the surface of the ﬁrst
kind of stones (type Va, Fig. 1a) is homogeneous, either
granular, made of crystals with blunted angles, or only
embossed. This morphology is commonly observed in
untreated cystinuric patients. When cystinuria is treated with
alkali or/and thiol therapy, a second type of cystine KS may
appear (type Vb, Fig. 1b). In our experience, all Vb KS were
observed in recurrent stone patients who had been treated
using alkalinizing agents (unpublished data). These Vb KS
exhibit a homogeneous, microcrystalline and smooth surface.
Note that some treated patients may also produce Va calculi.
These morphological types Va and Vb are in agreement with
other reports which suggest that rough and smooth types have
different behaviour when the stones are submitted to extra-
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corporeal shockwave lithotripsy (ESWL), the former being
more easily fragmented by ESWL (Bhatta et al., 1989).
Most reports on cystinuria have been devoted to the genetic
aspect or medical management (Pras, 2004; Dello Strologo et
al., 2002) but no study has investigated the structural para-
meters of cystine stones. Such structural characterization on
pathological calciﬁcations (Bazin, Daudon et al., 2012; Bazin &
Daudon, 2012) can be performed either through various
classical physical techniques (Evan et al., 2007; Rao et al., 2011;
Bazin et al., 2006), such as scanning electron microscopy
(SEM) (Gra`cia-Garcia et al., 2011; Dessombz, Me´ria et al.,
2011, 2012), micro-computerized tomography (Williams et al.,
2012; Kaiser et al., 2011), Fourier transform infrared (FTIR)
and Raman spectroscopy (Quy Dao & Daudon, 1997; Estepa
& Daudon, 1998; Guerra-Lopez et al., 2008; Wilson et al.,
2010), proton induced X-ray emission (Pineda-Vargas et al.,
2009), and laser ablation methods (Stepankova et al., 2013), or
through techniques speciﬁc to large instruments, such as micro
X-ray ﬂuorescence (Bazin et al., 2007), micro X-ray absorption
spectroscopy (Bazin et al., 2009; Carpentier et al., 2010;
Nguyen et al., 2011), micro FTIR spectroscopy (Dessombz,
Bazin et al., 2011) or neutron scattering (Bazin, Andre´ et al.,
2012).
The aim of this article is to relate morphological differences
observed at the macroscopic scale induced by the therapy to
structural characteristics at the mesoscopic and/or at the
nanometre scale. Such correlation has been established
recently for very particular whewellite kidney stones linked to
another genetic disease, namely primary hyperoxaluria
(Daudon et al., 2008; 2009). To attain this goal, a structural
investigation through SEM and powder neutron diffraction
(PND) has been performed. At this point, we introduce the
terms of nanocrystals and crystallites as deﬁned by Van
Meerssche & Feneau-Dupont (1973) in order to describe the
hierarchical structure of these pathological concretions.
Crystallites (measuring typically some tens of micrometres)
are made up of a collection of nanocrystals (measuring typi-
cally some hundreds of nanometres).
SEM gave us the opportunity to perform a direct observa-
tion of the morphology and the size of the crystallites at the
micrometre scale (Carpentier et al., 2009; Bazin, Andre´ et al.,
2012). At the nanometre scale, the average size of the nano-
crystals present in the crystallites was obtained through PND
(Bazin et al., 2006; Daudon et al., 2009; Bazin, Andre´ et al.,
2012).
2. Materials and methods
The biological samples (Table 1) analysed in the present
investigation came from Tenon Hospital. Regarding ethics, we
follow the usual procedures (Dessombz, Bazin et al., 2011;
Dessombz et al., 2012). All participants (adults or parents of
children participating in the study) gave their verbal consent,
documented by the researchers, for use of the material.
Samples were examined without knowledge of the name of the
patient or other identifying data. Ethical approval for the
study was obtained from the ethics committee of Tenon
Hospital. The investigation conformed to the principles of the
Declaration of Helsinki.
Twenty-ﬁve cystine KS were selected according to the
following criteria: (1) the stone material had to be large
enough (more than 30 mm3) to allow successive measurements
including sequential infrared analysis, SEM examination and
PND analysis; (2) clinical information had to be available
regarding sex and age of the patient, stone recurrence, and
accurate information on medical therapy. Stones from patients
who had received successive medical treatments including
alkalinizing drugs and/or thiol derivatives were excluded. All
the samples were ﬁrst investigated by stereomicroscopy and
FTIR spectroscopy (Quy Dao & Daudon, 1997; Estepa &
Daudon, 1998). All of them were examined by SEM while 24
samples were studied by PND. Selected clinical data from the
patients whose samples were studied have been gathered in
Table 1.
An FEI/Philips XL40 environmental scanning electron
microscope was used for characterization of the samples. An
important feature of the environmental scanning electron
microscope compared to a conventional scanning electron
microscope is the fact that nonconductive materials can be
imaged without any conductive coating, which permits a direct
observation with no damage for the sample. Imaging was
performed with a gaseous secondary electron detector, an
accelerating voltage of 20 kV and a water pressure of 0.4 torr
(53.3 Pa) in the chamber.
Neutron diffraction diagrams were collected on the G4.1
diffractometer at Laboratoire Le´on Brillouin at room
temperature. This beamline is equipped with a two-axis
powder diffractometer with a vertical focusing pyrolytic
graphite monochromator and an 800-cell multidetector
covering an 80 2 range (step 0.1 between two cells). More
research papers
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Figure 1
(a) Va cystine kidney stone, (b) Vb cystine kidney stones. The cross
section of a stone reveals a diffuse concentric structure in the periphery
and an unorganized agglomerate of cystine crystals in the core. (c) SEM
image of a typical Va cystine kidney stone made of large crystals
exhibiting ﬂat surfaces with well deﬁned corners and edges. The stone was
removed from the kidney of an untreated patient. (d) SEM image of a Vb
kidney stone.
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precisely, neutron diffraction diagrams were
collected using a wavelength of 2.4226 A˚,
with an acquisition time of a few hours on
samples without any preparation. Then the
mean size of the crystals for each sample
(Fig. 2) was calculated using the FullProf
program (Rodrı´guez-Carvajal, 2001;
Dahaoui et al., 1999). More precisely the
apparent mean size of the coherently
diffracting crystals was extracted from the
observed broadened Bragg peaks of the
PND stone diagrams taking into account the
instrumental resolution function of the
neutron diffractometer. The FullProf
program provided a value of this mean size
with its standard deviation.
The size of the crystallites (measured
using the environmental scanning electron
microscope) in micrometres is expressed as
mean  SE (standard error). In order to
obtain a signiﬁcant average size for the
crystallites, the complete set of observations
performed on the different samples has been
considered. For each observation, we
consider all crystallites for which we
measure a size. In Fig. 2, we show a typical
set of measurements. The size of the nano-
crystals (measured through PND) is
expressed in nanometres as mean  SE. All
statistical comparisons were performed
using the Mann–Whitney test or Student t
test for continuous variables. Statistical
signiﬁcance was deﬁned as a p value less
than 0.05.
3. Results
A ﬁrst investigation through SEM was
performed on a set of samples coming from seven untreated
patients (patients 1–7 in Table 1). As an example, the SEM
image in Fig. 1(c) shows a typical cystine stone (untreated
patient) made of large crystals exhibiting ﬂat surfaces with
well deﬁned corners and edges, a result in line with the
hexagonal structure of cystine. At the opposite extreme, the
typical morphology of crystallites coming from patients
treated with sodium bicarbonate in our series (patients 8–11 in
Table 1) is less well deﬁned (Fig. 1d). Moreover, from a more
detailed inspection of Figs. 1(c) and 1(d), a signiﬁcant differ-
ence was observed regarding the size of hexagonal plates
(75.5  12.2 mm versus 23.5  2.8 mm, p = 0.0004).
Figs. 3(a) and 3(b) illustrate two examples of SEM micro-
graphs of stones observed in patients receiving either Foncitril
(Fig. 3a) or Alcaphor (Fig. 3b) as alkalinization therapy. Note
that cystine crystals seem poorly affected by the latter treat-
ment.
Finally, cystine KS coming from patients treated with thiol
derivatives (tiopronine, d-penicillamine, captopril) have been
research papers
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Figure 2
Typical ﬁnal observed (Yobs in red), calculated (Ycalc) and difference
proﬁles (Yobs-Ycalc in blue) of the PND diagram of a cystine kidney
stone. Tick marks (Bragg position in green) below the proﬁles indicate
the peak positions of allowed Bragg reﬂections for cystine.
Table 1
Clinical data on selected samples.
MSR = multiple stones recurrences. NA = not assessed.
Sample Sub-type Sex Age Therapy Clinical data Crystal size (nm)
Untreated patients
1 Va M 29 No treatment MSR Above 200
2 Va M 28 No treatment MSR. No diagnostic
before stone analysis
Above 200
3 Va M 26 No treatment 1st stone episode (bilat-
eral kidney stones)
Above 200
4 Va F 3 No treatment 1st stone Above 200
5 Va M 25 No treatment MSR Above 200
6 Va M 25 No treatment MSR Above 200
7 Va M 40 No treatment MSR Above 200
Alkalinization with sodium bicarbonate
8 Vb M 23 Sodium bicarbonate MSR 72  3
9 Vb F 41 Sodium bicarbonate MSR. Previous
nephrectomy
94  6
10 Vb M 34 Sodium bicarbonate MSR 147  10





Alkalinization with other salts












15 Va F 27 Potassium citrate MSR Above 200
Sulfhydryls
16 Va F 35 Tiopronine MSR Above 200
17 Va F 25 Tiopronine MSR Above 200
18 Va M 30 Tiopronine MSR NA
19 Va F 52 Tiopronine MSR Above 200
20 Va M 19 d-Penicillamine MSR Above 200
21 Va F 36 d-Penicillamine MSR Above 200
22 Va M 30 d-Penicillamine MSR. Kidney atrophy Above 200
23 Va M 26 Captopril MSR Above 200
24 Va M 26 Captopril MSR Above 200
25 Va M 48 Captopril MSR Above 200
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examined also through SEM (Figs. 4a, 4b and 4c, respectively).
Some signiﬁcant differences exist regarding the surfaces of
these cystine KS, suggesting some signs of cystine crystal
dissolution for tiopronine- or d-penicillamine-treated patients
but not for stones in patients under captopril therapy.
The structural parameters determined for the biological
samples show little deviation from those already published
(Dahaoui et al., 1999). For the seven untreated patients
(subjects 1–7, Table 1), the mean size of the nanocrystals was
above 200 nm, the upper limit for our experimental setup.
Conversely, for the patients treated with alkalinization by
sodium bicarbonate, the mean size of the nanocrystals was
signiﬁcantly lower (138 nm, p = 0.003) and ranged from 70 to
170 nm (subjects 8–11, Table 1). It is of note that all the
corresponding stones exhibit a Vb type. Finally, stones from all
patients treated with other alkalinizing drugs (subjects 12–15,
Table 1) or with thiol derivatives (subjects 16–25) were
composed of cystine nanocrystals above 200 nm. The stone
type was Va in all cases.
4. Discussion
Although cystine is known as only one crystalline phase in
urine, two different stone morphologies, Va and Vb, have been
described in patients, with two different behaviours when
treated by ESWL (Bhatta et al., 1989; Daudon et al., 1993). To
explain this difference, we investigated the structural char-
acteristics of these two types of stones at the macroscopic,
mesoscopic and nanometric scales.
At the macroscopic scale, the average size of Va KS coming
from treated or untreated patients was (mean  standard
deviation) 8.9  6.1 mm (range 0.8–39 mm) versus 4.9 
2.5 mm (range 1.5–11 mm) for Vb KS from treated patients
(p < 0.001). Considering that the maximum size for sponta-
neous passage of stones is around 6 mm, this difference in
stone size could be clinically very important because Vb-type
stones, owing to their reduced dimensions, may easily pass
without any urological procedures while Va stones often
require urological treatment. Indeed, in our experience, based
on 730 cystine stones analysed in our laboratory, Vb stones are
about ten to 20 times less frequent than Va stones, and the
latter stone type may also be observed in patients treated long
term with sodium bicarbonate. In fact, we identiﬁed four
patients who formed Va stones while receiving only that
treatment. Unfortunately, their stones or fragments were too
small to allow us to apply all of our analytical procedures on
the same sample as done in the present work.
At the mesoscopic scale, a signiﬁcant difference in mean
crystallite size was observed between Va stones from treated
and untreated patients and Vb stones from treated patients
(75.5 versus 23.5 mm, p = 0.0004). Finally, at the nanometric
scale, the mean size of nanocrystals was signiﬁcantly lower for
Vb stones (138 versus more than 200 nm for Va stones). Thus,
as a preliminary conclusion, the complete set of data shows
that, from nanometric to macroscopic scales, Vb and Va stones
seem to be signiﬁcantly different.
research papers
722 Dominique Bazin et al.  Cystine kidney stones at the mesoscopic and nanometre scale J. Appl. Cryst. (2014). 47, 719–725
Figure 4
(a) Signiﬁcant erosion of the surface of cystine crystals in a patient treated
with tiopronine. Note the hexagonal holes which correspond to dissolved
small cystine crystals. Large ones have lost their typical hexagonal shape.
(b) Similar alteration of the cystine crystals in a stone from a patient
treated with d-penicillamine as observed with tiopronine. (c) Example of
impaired surface of cystine crystals displaying numerous scattered holes
similar to wormholes in a stone from a patient treated with captopril. The
bulk of the crystals is not affected by such a treatment.
Figure 3
(a) SEM image of a cystine stone from a patient treated with Foncitril. We
can see the coexistence of well deﬁned cystine crystals with a plane
surface and altered crystals with a rough surface. Note the presence of
deposited spherical particles of apatite (arrows) as a consequence of the
increased pH in urine owing to therapy. (b) Poorly affected cystine
crystals in a patient treated with Alcaphor. The crystal edges are still well
deﬁned, suggesting a limited effect of the treatment.
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The second major ﬁnding of this investigation was the
observation of different alterations of the crystal surface at the
mesoscopic scale related to the medical treatment. In the case
of Foncitril (patient 12), Fig. 3(a) exhibits at the same time
well deﬁned cystine crystals with a plane surface and altered
crystals with a rough surface. Note the presence of deposited
spherical particles of apatite (arrow) as a consequence of the
increased pH in urine resulting from therapy. For patients 13
and 14, treated with Alcaphor, the crystal edges are still well
deﬁned, suggesting a limited effect of the treatment (Fig. 3b).
Regarding patients treated with thiol derivatives, another
kind of erosion was observed at the surface of cystine crystals
(Fig. 4). In patients treated with tiopronine (subjects 16–19,
Fig. 4a), hexagonal holes were observed, which seem to
correspond to dissolved small cystine crystals. It is of note that
the large crystals have lost their typical hexagonal shape, also
suggesting the beginning of a dissolution process. Such
dissolution of cystine stones has already been reported
(suggested) in the literature (Lotz & Bartter, 1965; Lindell et
al., 1995). Similar alterations of cystine crystals as seen with
tiopronine were observed for patients (subjects 20–22, Fig. 4b)
treated with d-penicillamine. Because the patient also
received recommendation for alkalinizing his or her urine,
small spherical entities made of carbapatite as indicated by
FTIR spectroscopy are also present in the stone. Finally, even
if it seems that the bulk of the crystals is not affected by
captopril therapy (subjects 23–25, Fig. 4c), the impaired
surfaces of the cystine crystals display numerous scattered
holes similar to wormholes. The limited effect of captopril on
cystine crystals in comparison to that observed for tiopronine
and d-penicillamine is in agreement with clinical ﬁndings
suggesting the failure of captopril in preventing stone recur-
rence (Aunsholt & Ahlbom, 1990). Indeed, in our crystalluria
studies, we were unable to demonstrate any signiﬁcant effect
of captopril for reducing cystine crystal volume, while a
signiﬁcant decrease in crystal volume was observed in patients
treated by either tiopronine or d-penicillamine (Daudon et al.,
2003). It is well known that tiopronine and d-penicillamine are
able to form soluble complexes with cysteine, thus reducing
signiﬁcantly the amount of cysteine available to form cystine
in urine (Meiouet et al., 2011). As a consequence, the relative
supersaturation for cystine is signiﬁcantly reduced and cystine
solubility improved (Asplin & Asplin, 2012), especially if, in
addition, the urine volume is signiﬁcantly increased (above
3 l d1) along with urine pH (pH 7.5), thus allowing
previously formed crystals to dissolve at least to a certain
extent.
Thus, at the nanometric scale, PND shows that the nano-
crystal’s size is lower for patients under classical alkalinization
based on sodium bicarbonate than for untreated patients and
patients treated with any other drug including thiol derivatives
or alkalizing drugs such as trometamol or citrate salts. Thus, a
ﬁrst salient point of this study lies in the fact that only the
usual alkaline therapy signiﬁcantly reduces the growing
process of cystine crystals. As underlined previously (Tiselius,
2010), high urine pH seems to be a key point for preventing
stone recurrence. This is in agreement with our studies on
cystine crystalluria related to urine pH: the higher the urine
pH, the lower the crystal volume of cystine in urine. Moreover,
we have already shown that all patients with a high crystal
volume of cystine in urine (above 3000 mm3 mm3), which
corresponds to large crystallite aggregates, developed new
stones, while patients with a lower crystal volume did not
(Daudon et al., 2003).
Citrate salts would not be able to sufﬁciently increase urine
pH to effectively reduce crystal growth by comparison with
bicarbonate salts. At this point of the discussion, it is worth
underlining that the medical therapy based on high ﬂuid
intake, alkalinization or thiol administration may be consid-
ered as a cyclic process. Each administration of the alkali-
nizing drug results in a signiﬁcant but temporary increase in
urine pH, both in the different parts of the nephron and in the
ﬁnal urine, followed by a subsequent slow decrease up to the
next intake of the drug. It is the same for the dilution of the
urine following water intake. As a result of this cycle, the
cystine saturation is varying in urine, with other factors such as
diet and metabolism also inﬂuencing its excretion. Thus, it may
be difﬁcult to avoid crystal formation over extended periods of
time. As a consequence, stone recurrence is a frequent ﬁnding
in cystinuric patients while under medical therapy, because it is
not so easy to optimize day-to-day water intake, urine pH and
diet. Perhaps Vb stones with small nanocrystals and crystal-
lites are observed only in the most compliant patients able to
maintain urine pH in the highest range. However that may be,
our ﬁndings suggest that therapeutic measures are able to
modify the structural characteristics of cystine KS.
As recently reported by Asplin &Asplin (2012), the efﬁcacy
of thiol derivatives requires high urine pH, underlining the
clinical beneﬁt of simultaneous treatment by alkalinizing
agents and thiol derivatives rather than by sulfhydryl alone.
Promising results provided by Rimer and coworkers suggest
that l-cystine methyl esters could be efﬁcient molecules able
to reduce cystine crystal formation (Rimer et al., 2010). In vivo
studies remain to be performed in order to validate the results
and assess potential side effects.
On the basis of current medical treatment, our study by
SEM examination has pointed out signiﬁcant differences in
the average size of the crystallites between untreated patients
and patients treated with alkalinization. The complete set of
structural results shows that the usual alkalinization process
not only reduces the size of the cystine nanocrystals as shown
by PND but also limits their agglomeration, i.e. the size of the
crystallites is ﬁnally smaller. These results clearly demonstrate
the effect of alkalinization by sodium bicarbonate in cystinuric
patients. Is it a real beneﬁt to form Vb rather than Va stones?
Although smaller in size, Vb stones are often more numerous
than Va stones (9.1 versus 5.5 per patient). As a consequence,
spontaneous and easy passage of the stones cannot be guar-
anteed. Nevertheless, the change from Va to Vb stones is
highly suggestive of the beneﬁt of therapy on crystal forma-
tion, which is a prerequisite to reduce stone recurrence.
On the other hand, thiol therapy based on tiopronine or
d-penicillamine, not on captopril treatment, seems able to
help in solubilizing cystine crystals, at least in part, suggesting
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the potential in clinical practice to combine alkalinization and
thiol derivatives. Because of the reduced agglomeration of the
crystallites, we can expect also a decrease in the size of KS and
a facilitation of their spontaneous passage. As underlined
above, we observed a signiﬁcantly reduced size of stones in
such treated patients when compared with other therapies.
If the Vb stone type is a beneﬁt for the patient is another
question. First, because all Vb stones were found as recurrent
stones in treated patients, they may be considered as a failure
of medical therapy. Second, this stone type appears to be
infrequent. Nevertheless, what we can conclude from our
investigations is that different effects on cystine crystals may
be observed according to the treatment. However, an impor-
tant limitation in our results is that we cannot ensure the
actual compliance of the patients regarding the proposed
drugs, especially over months or years. The high recurrence
rate of stones in medically managed cystinuric patients as
previously reported (Barbey et al., 2000) is highly suggestive of
a poor compliance of the patients despite evidence for a
signiﬁcant beneﬁcial effect of the treatment.
5. Conclusions
In agreement with the results reported for ESWL treatment,
SEM examination and PND analysis provide evidence that
signiﬁcant structural differences exist between Va and Vb
kidney stones at different scales. Moreover, among the
different medical treatments, alkalinization with sodium
bicarbonate seems to affect cystine kidney stones at the
micrometre and nanometre scales, reducing the size of both
nanocrystals and crystallites, while other medical treatments
only alter the surface of the crystallites. Even though the
number of patients is small (25), the results provide evidence
that the various treatments are associated with very different
modiﬁcations in the cystine crystal surface. Thus, such an
approach helps to assess the interaction between drugs and
cystine stones and is more generally applicable to the study of
pathological calciﬁcations.
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